SEPTAD

Alzheimer’s disease remains a major global health burden, with current therapies providing limited symptomatic benefit and minimal impact on the underlying neurodegenerative process. remynd targets a central driver of the disease: dysregulated neuronal calcium homeostasis, which contributes to synaptic failure, neuronal loss, and the accumulation of Aβ and tau pathology. Its therapeutic approach restores this imbalance by modulating septin-6, an essential regulator of neuronal cytoskeletal integrity. REM392 is a small, orally available septin modulator designed to normalise calcium signalling selectively in diseased neurons while maintaining a favourable safety profile. Extensive non-clinical studies demonstrate broad and robust effects, including restored synaptic plasticity, improved network function, and reduction of pathological Aβ and tau species. A completed Phase 2a trial with a first-generation compound REM127 confirms the mechanism’s translation to patients, showing improvements across biomarkers and functional readouts with a large effect size for the patients. A Phase 1 single ascending dose clinical trial for REM392 demonstrated favourable safety and PK supporting further REM392’s advancement. The next stage will prepare REM392 for Phase 2b and the pathway toward partnering. With its unique mechanism, strong translational evidence, and potential to provide both symptomatic improvement and disease modification as simple oral dose form, REM392 aims to address the large unmet need across mild to moderate Alzheimer’s disease and reduce the long-term healthcare and societal burden associated with the condition.